These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date 2004-002176-42 Open randomized study to evaluate the efficacy of i.v. iron support (ferrum gluconate, 125 mg i.v. infusion weekly for 6 weeks) in primary solid tumour patients (breast, lung, colon-rectum and gynecol... bad-data
Listed as ongoing, but also has a completion date 2005-001300-39 A phase 2, multi-centre, randomized, double-blind, placebo-controlled, parallel-group 3 arms pilot study to assess the efficacy, the safety and the pharmacokinetics of two treatment schedules of rep... 2008-06-19 bad-data
Not reported 2010-019424-31 A phase 2 multicenter, randomized, open label, parallel assignment, pilot study to assess the efficacy and safety of reparixin following a single infusion islet transplantation in patients with type... 2013-04-30 due-trials
Not reported Terminated 2011-000756-42 A phase 2, multicentre, single arm, pilot study to assess the efficacy and the safety of 150 mg twice a day oral DF2156A in patients with active bullous pemphigoid. 2012-07-11 due-trials
Reported results 2011-006201-10 A phase 3, multicenter, randomized, double-blind, parallel assignment study to assess the efficacy and safety of reparixin in pancreatic islet transplantation 2016-12-09 due-trials
Exempt, with results 2012-002527-15 Study Brand Name : REPARO 2016-05-19 not-yet-due
Not reported 2013-002244-86 Effect of reparixin on long-term outcomes after pancreatic islet 2015-06-23 due-trials
Reported results 2013-004271-12 An open-label study evaluating safety and efficacy of recombinant human nerve growth factor (rhNGF) eye drops at different doses in patients with Dry Eye 2015-01-30 due-trials
Ongoing 2014-003968-20 A phase 2, multicentre, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes not-yet-due
Ongoing 2014-004796-23 A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer... not-yet-due
Not reported 2016-002172-27 A 8 weeks, Phase II, single-centre, randomized, double-masked, vehicle-controlled, parallel group study with 4 weeks of follow-up to evaluate preliminary efficacy and safety of recombinant human Nerve... 2017-09-04 due-trials